Company intelligence / Profile preview

Maijin Biomedical Technology

上海（Shanghai）, 上海市（Shanghai）, 中国（China）majinpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Maijin Biomedical Technology has a pipeline focused on immunology and autoimmune disorders. Its lead assets include izokibep for plaque psoriasis in Phase 3, IMG‑016 for thrombocytopenia in Phase 3, and several other biologics targeting immune pathways in earlier clinical stages. The company is advancing multiple monoclonal antibodies and bispecifics through clinical trials.

Therapeutic areas: DermatologyImmunologyHematology
Modalities: Monoclonal antibodySmall moleculeFusion proteinBispecific monoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

MG2512

1 more asset in the full pipeline.

Request access →

Partnerships

Affibody AB [izokibep development partnership]Inmagene Biopharmaceuticals [collaborative development noted]

Beyond the preview

Go deeper on Maijin Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maijin Biomedical Technology.

Explore the full profile